All In Biotech

Drug Trial Radar · NCT05706623

A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function

A Phase 1, Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function

Last checked: Nov 19, 2026Latest source record: Jul 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

16

Actual

Start

Jan 30, 2023

Primary completion

Apr 4, 2023

Study completion Apr 4, 2023

Sponsor

Lead sponsor
VectivBio AGIndustry
Sponsor type
Industry
First posted
Jan 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective is to assess the pharmacokinetics (PK) of apraglutide in subjects with hepatic impairment compared with matched control subjects with normal hepatic function following single subcutaneous (SC) dose administration.

Conditions

  • Hepatic Impairment

Interventions

  • ApraglutideDrug

    Single dose of apraglutide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Curve to Infinity (AUCinf) of ApraglutideTime frame: Pre-dose Day 1; 6, 12, 24, 28, 36, 40, 48, 60, 72, 96, 120, 144, 168, 240, and 312 hours post-dose
  2. Area Under the Curve (AUC) From Time Zero to 168 Hours Post-dose (AUC0-168h) of ApraglutideTime frame: Pre-dose Day 1; 6, 12, 24, 28, 36, 40, 48, 60, 72, 96, 120, 144, and 168 hours post-dose
  3. Maximum Observed Plasma Concentration (Cmax) of ApraglutideTime frame: Pre-dose Day 1; 6, 12, 24, 28, 36, 40, 48, 60, 72, 96, 120, 144, 168, 240, and 312 hours post-dose

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • APEX

    Münich, Germany

  • Summit Clinical Research

    Bratislava, Slovakia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.